Airway Therapeutics, a Sharonville, Ohio-based biotechnology company working to prevent a debilitating lung condition in extremely premature infants, secured $4.6m in Series A financing.
The company intends to use the funds to continue to develop its AT-100.
Led by CEO Marc Salzberg, MD, Airway Therapeutics has developed a protein, recombinant human surfactant protein D (AT-100), that could prevent Bronchopulmonary Dysplasia (BPD), a chronic lung disease that develops in preterm infants who require ventilation shortly after birth.
Pre-clinical data suggest treatment with Airway’s AT-100, in addition to the commercial surfactant that is currently available, effectively prevents the infection and lung damage than does the current standard of care.
Both the US Food and Drug Administration and European regulators granted orphan designation to Airway.